Renal Dysfunction With Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin Therapy

Acta Hepatologica Japonica - Japan
doi 10.2957/kanzo.53.425
Full Text
Abstract

Available in full text

Categories
Hepatology
Date
Authors
Publisher

Japan Society of Hepatology

Related search

Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection

Eastern Mediterranean Health Journal
Medicine
2011English

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

Gastroenterology
HepatologyGastroenterology
2011English

Prediction of Anemia in Triple Therapy With Peginterferon ^|^alpha;-2b, Ribavirin, and Telaprevir for Patients With Chronic Hepatitis C From the Viewpoint of Renal Function

Acta Hepatologica Japonica
Hepatology
2013English

Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C

Archives of Internal Medicine
2004English

Cost-Effectiveness Analysis of Treatment With Peginterferon-Alfa-2a Versus Peginterferon-Alfa-2b for Patients With Chronic Hepatitis C Under the Public Payer Perspective in Brazil

Cost Effectiveness and Resource Allocation
Health Policy
2013English

Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response

Hepatology
MedicineHepatology
2010English

PGI18 Treatment of Chronic Hepatitis C Patients With Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Side Effects of Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis-C

Internal Medicine
Internal MedicineMedicine
2007English

Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

The Lancet
Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy